Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies

Reuters

2025/09/04

Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies

Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. $(ELAB)$, has announced the successful completion of Phase II of its AI Development Program in partnership with Yuva Biosciences, Inc. This collaborative effort leverages YuvaBio's MitoNova™ AI platform to discover and develop novel treatments for obesity, type 2 diabetes, and other cardiometabolic conditions. During Phase II, YuvaBio compiled a collection of small molecule candidates from 12 curated libraries, focusing on molecules with potential activity in key disease areas such as obesity and cardiometabolic disorders. These candidates were shortlisted based on their predicted impact on muscle preservation and metabolic health, ready for further biological validation and potential advancement to experimental testing and clinical development by Northstrive.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523447-en) on September 04, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564370270"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564370270\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564370270?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564370270","market":"nz","top_or_hot":-1,"title":"Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. <a href=\"https://laohu8.com/S/ELAB\">$(ELAB)$</a>, has announced the successful completion of Phase II of its AI Development Program in partnership with Yuva Biosciences, Inc. This collaborative effort leverages YuvaBio's MitoNova™ AI platform to discover and develop novel treatments for obesity, type 2 diabetes, and other cardiometabolic conditions. During Phase II, YuvaBio compiled a collection of small molecule candidates from 12 curated libraries, focusing on molecules with potential activity in key disease areas such as obesity and cardiometabolic disorders. These candidates were shortlisted based on their predicted impact on muscle preservation and metabolic health, ready for further biological validation and potential advancement to experimental testing and clinical development by Northstrive.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523447-en) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNorthstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-04 21:54</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. <a href=\"https://laohu8.com/S/ELAB\">$(ELAB)$</a>, has announced the successful completion of Phase II of its AI Development Program in partnership with Yuva Biosciences, Inc. This collaborative effort leverages YuvaBio's MitoNova™ AI platform to discover and develop novel treatments for obesity, type 2 diabetes, and other cardiometabolic conditions. During Phase II, YuvaBio compiled a collection of small molecule candidates from 12 curated libraries, focusing on molecules with potential activity in key disease areas such as obesity and cardiometabolic disorders. These candidates were shortlisted based on their predicted impact on muscle preservation and metabolic health, ready for further biological validation and potential advancement to experimental testing and clinical development by Northstrive.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523447-en) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"個人用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDLbQm3y6:1","article_id":"2564370270","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564370270","pubTimestamp":1756994064,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. , has announced the successful completion of Phase II of its AI Development Program in partnership with Yuva Biosciences, Inc. This collaborative effort leverages YuvaBio's MitoNova AI platform to discover and develop novel treatments for obesity, type 2 diabetes, and other cardiometabolic conditions. During Phase II, YuvaBio compiled a collection of small molecule candidates from 12 curated libraries, focusing on molecules with potential activity in key disease areas such as obesity and cardiometabolic disorders. These candidates were shortlisted based on their predicted impact on muscle preservation and metabolic health, ready for further biological validation and potential advancement to experimental testing and clinical development by Northstrive.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","ELAB":"PMGC Holdings","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"PMGC Holdings子公司Northstrive Biosciences完成肥胖治疗人工智能项目的第二阶段","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ELAB":0.9},"content_text":"Northstrive Biosciences, a PMGC Holdings Subsidiary, Completes Phase II of AI Program for Obesity Therapies\n    \n\n        Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. $(ELAB)$, has announced the successful completion of Phase II of its AI Development Program in partnership with Yuva Biosciences, Inc. This collaborative effort leverages YuvaBio's MitoNova™ AI platform to discover and develop novel treatments for obesity, type 2 diabetes, and other cardiometabolic conditions. During Phase II, YuvaBio compiled a collection of small molecule candidates from 12 curated libraries, focusing on molecules with potential activity in key disease areas such as obesity and cardiometabolic disorders. These candidates were shortlisted based on their predicted impact on muscle preservation and metabolic health, ready for further biological validation and potential advancement to experimental testing and clinical development by Northstrive.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523447-en) on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}